

# Dawn L Hershman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1824209/publications.pdf>

Version: 2024-02-01

398  
papers

18,451  
citations

14655  
66  
h-index

16183  
124  
g-index

408  
all docs

408  
docs citations

408  
times ranked

22332  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association Between Health-Related Quality of Life and Progression-Free Survival in Patients With Advanced Cancer: A Secondary Analysis of SWOG Clinical Trials. <i>JCO Oncology Practice</i> , 2022, 18, e442-e451.	2.9	5
2	Cognitive Functioning and Health in Hispanic/Latina Breast Cancer Survivors. <i>Journal of Immigrant and Minority Health</i> , 2022, 24, 597-604.	1.6	3
3	Association Between Neighborhood Socioeconomic Inequality and Cervical Cancer Incidence Rates in New York City. <i>JAMA Oncology</i> , 2022, 8, 159.	7.1	5
4	Diagnosis of Leptomeningeal Metastasis in Women With Breast Cancer Through Identification of Tumor Cells in Cerebrospinal Fluid Using the CNSideâ„¢ Assay. <i>Clinical Breast Cancer</i> , 2022, 22, e457-e462.	2.4	6
5	S1417CD: A Prospective Multicenter Cooperative Group-Led Study of Financial Hardship in Metastatic Colorectal Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2022, 114, 372-380.	6.3	28
6	Risk of Cardiometabolic Risk Factors in Women With and Without a History of Breast Cancer: The Pathways Heart Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 1635-1646.	1.6	27
7	Adoption of minimally invasive surgery after neoadjuvant chemotherapy in women with metastatic uterine cancer. <i>Gynecologic Oncology</i> , 2022, 164, 341-347.	1.4	1
8	Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials. <i>Journal of Clinical Oncology</i> , 2022, 40, 1474-1486.	1.6	102
9	Abstract P4-11-16: Feasibility and patient satisfaction with a smartphone application to improve medication adherence among patients with breast cancer. <i>Cancer Research</i> , 2022, 82, P4-11-16-P4-11-16.	0.9	0
10	Abstract P4-11-33: Continuous glucose monitoring and hyperglycemia during chemotherapy for early-stage breast cancer. <i>Cancer Research</i> , 2022, 82, P4-11-33-P4-11-33.	0.9	0
11	Abstract PD8-07: Evaluation of Tucatinib + (Paclitaxel + Pertuzumab + Trastuzumab) followed by AC in high-risk HER2 positive (HER2+) stage II/III breast cancer: Results from the I-SPY 2 TRIAL. <i>Cancer Research</i> , 2022, 82, PD8-07-PD8-07.	0.9	0
12	Abstract P3-02-04: Prediction of breast cancer response to neoadjuvant chemotherapy in different biological breast cancer subtypes using diffuse optical tomography. <i>Cancer Research</i> , 2022, 82, P3-02-04-P3-02-04.	0.9	0
13	Abstract P4-11-04: A randomized adaptive sequential selection trial of cryotherapy, compression therapy, and placebo to prevent taxane induced peripheral neuropathy in patients with breast cancer. <i>Cancer Research</i> , 2022, 82, P4-11-04-P4-11-04.	0.9	1
14	Pathologic characteristics, patterns of care, and outcomes of Asian-Americans and Pacific islanders with uterine cancer. <i>Gynecologic Oncology</i> , 2022, 165, 160-168.	1.4	2
15	Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 1647-1658.	1.6	46
16	Trends in human papillomavirus vaccination among women aged 27 to 45 years, from 2017 to 2019. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 568-570.e1.	1.3	0
17	Successes and challenges of implementing a cancer care delivery intervention in community oncology practices: lessons learned from SWOG S1415CD. <i>BMC Health Services Research</i> , 2022, 22, 432.	2.2	1
18	Associations Between Acculturation and Weight, Diet Quality, and Physical Activity Among Latina Breast Cancer Survivors: The Â¡Mi Vida Saludable! Study. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2022, 122, 1703-1716.	0.8	3

#	ARTICLE	IF	CITATIONS
19	The Breast Cancer Weight Loss trial (Alliance A011401): A description and evidence for the lifestyle intervention. <i>Obesity</i> , 2022, 30, 28-38.	3.0	9
20	Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 1696-1698.	1.6	22
21	Risk of heart failure with preserved versus reduced ejection fraction in women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 669-675.	2.5	4
22	Use of a convolutional neural network-based mammographic evaluation to predict breast cancer recurrence among women with hormone receptor-positive operable breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, , .	2.5	2
23	Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1963.	7.4	81
24	New persistent opioid use among adolescents and young adults with sarcoma. <i>Cancer</i> , 2022, 128, 2777-2785.	4.1	6
25	Use of Immune Checkpoint Inhibitors in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A. <i>JCO Oncology Practice</i> , 2022, 18, 649-651.	2.9	2
26	Relative importance of individual insurance status and hospital payer mix on survival for women with cervical cancer. <i>Gynecologic Oncology</i> , 2022, , .	1.4	3
27	Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With Survival. <i>Journal of the National Cancer Institute</i> , 2021, 113, 54-63.	6.3	98
28	The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32. <i>Journal of the National Cancer Institute</i> , 2021, 113, 192-198.	6.3	24
29	“When Offered to Participate” A Systematic Review and Meta-Analysis of Patient Agreement to Participate in Cancer Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2021, 113, 244-257.	6.3	116
30	Less radical surgery for early-stage cervical cancer: a systematic review. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 348-358.e5.	1.3	19
31	Better Together: Clinical and Genomic Data to Inform Shared Decision Making. <i>Journal of Clinical Oncology</i> , 2021, 39, 545-547.	1.6	1
32	Cost of care for the initial management of cervical cancer in women with commercial insurance. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 286.e1-286.e11.	1.3	9
33	Opioid use and misuse in children, adolescents, and young adults with cancer: a systematic review of the literature. <i>Supportive Care in Cancer</i> , 2021, 29, 4521-4527.	2.2	6
34	Changes in Diffuse Optical Tomography Images During Early Stages of Neoadjuvant Chemotherapy Correlate with Tumor Response in Different Breast Cancer Subtypes. <i>Clinical Cancer Research</i> , 2021, 27, 1949-1957.	7.0	5
35	Patient-Reported Outcomes and Long-Term Nonadherence to Aromatase Inhibitors. <i>Journal of the National Cancer Institute</i> , 2021, 113, 989-996.	6.3	13
36	Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer. <i>JAMA Oncology</i> , 2021, 7, 246.	7.1	34

#	ARTICLE	IF	CITATIONS
37	Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients. Gynecologic Oncology, 2021, 160, 793-799.	1.4	11
38	Persistent Disparity: Socioeconomic Deprivation and Cancer Outcomes in Patients Treated in Clinical Trials. Journal of Clinical Oncology, 2021, 39, 1339-1348.	1.6	62
39	Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN). JCO Oncology Practice, 2021, 17, e1821-e1829.	2.9	4
40	Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer. Breast Cancer Research and Treatment, 2021, 188, 427-432.	2.5	12
41	Patient factors associated with time to medication receipt of oral anti-cancer drugs.. Journal of Clinical Oncology, 2021, 39, 1519-1519.	1.6	0
42	Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. Journal of Clinical Oncology, 2021, 39, 1485-1505.	1.6	395
43	Inequity in location and quality of death of advanced cancer patients by immigrant status.. Journal of Clinical Oncology, 2021, 39, 12036-12036.	1.6	0
44	Use of fertility preservation services in male reproductive-aged cancer patients. Gynecologic Oncology Reports, 2021, 36, 100716.	0.6	6
45	Long-term results from a randomized blinded sham- and waitlist-controlled trial of acupuncture for joint symptoms related to aromatase inhibitors in early stage breast cancer (S1200).. Journal of Clinical Oncology, 2021, 39, 12018-12018.	1.6	2
46	Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial. Npj Breast Cancer, 2021, 7, 74.	5.2	16
47	New and persistent controlled substance use among patients undergoing mastectomy and reconstructive surgery. Breast Cancer Research and Treatment, 2021, 189, 445-454.	2.5	5
48	Trends in ovarian conservation and association with survival in premenopausal patients with stage I leiomyosarcoma. Gynecologic Oncology, 2021, 161, 734-740.	1.4	2
49	Association of New Perioperative Benzodiazepine Use With Persistent Benzodiazepine Use. JAMA Network Open, 2021, 4, e2112478.	5.9	13
50	Challenges and opportunities to developing a frailty index using electronic health record data. Journal of Geriatric Oncology, 2021, 12, 851-854.	1.0	7
51	Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer. Breast Cancer Research and Treatment, 2021, 189, 177-185.	2.5	15
52	Abstract 645: Network-based assessment of HDAC6 activity is highly predictive of pre-clinical and clinical responses to the HDAC6 inhibitor ricolinostat. , 2021, , .		0
53	Fragmentation of surgery and chemotherapy in the initial phase of ovarian cancer care and its association with overall survival. Gynecologic Oncology, 2021, 162, 56-64.	1.4	9
54	Diffuse optical tomography breast imaging measurements are modifiable with pre-surgical targeted and endocrine therapies among women with early stage breast cancer. Breast Cancer Research and Treatment, 2021, 189, 297-304.	2.5	2

#	ARTICLE	IF	CITATIONS
55	Cancer Clinical Trial Participation at the 1-Year Anniversary of the Outbreak of the COVID-19 Pandemic. JAMA Network Open, 2021, 4, e2118433.	5.9	35
56	Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo. JNCI Cancer Spectrum, 2021, 5, pkab066.	2.9	5
57	Care Delivery Impact of the COVID-19 Pandemic on Breast Cancer Care. JCO Oncology Practice, 2021, 17, e1215-e1224.	2.9	36
58	¡Mi Vida Saludable! A randomized, controlled, 2×2 factorial trial of a diet and physical activity intervention among Latina breast cancer survivors: Study design and methods. Contemporary Clinical Trials, 2021, 110, 106524.	1.8	16
59	Adolescent and young adult enrollment to a National Cancer Institute-sponsored National Clinical Trials Network Research Group over 25 years. Cancer, 2021, 127, 4574-4584.	4.1	11
60	In Reply. Obstetrics and Gynecology, 2021, 138, 310-311.	2.4	0
61	Association of Fatigue and Outcomes in Advanced Cancer: An Analysis of Four SWOG Treatment Trials. JCO Oncology Practice, 2021, 17, e1246-e1257.	2.9	8
62	Adherence to PARP inhibitor therapy among women with ovarian cancer. Gynecologic Oncology, 2021, 163, 262-268.	1.4	7
63	Association Between Overall Survival and the Tendency for Cancer Programs to Administer Neoadjuvant Chemotherapy for Patients With Advanced Ovarian Cancer. JAMA Oncology, 2021, 7, 1782.	7.1	21
64	Preference-weighted quality of life: Findings from the Selenium and Vitamin E Cancer Prevention Trial (SELECT).. Journal of Clinical Oncology, 2021, 39, 144-144.	1.6	0
65	Integration of germline multigene panel testing into breast and gynecologic oncology clinics.. Journal of Clinical Oncology, 2021, 39, 164-164.	1.6	0
66	Incorporating systematic financial screening into the electronic health record.. Journal of Clinical Oncology, 2021, 39, 184-184.	1.6	0
67	Factors associated with failure to receive oral anticancer drugs.. Journal of Clinical Oncology, 2021, 39, 41-41.	1.6	0
68	Association between insurance plan, prior authorization, and time to receipt of oral anticancer drugs.. Journal of Clinical Oncology, 2021, 39, 6-6.	1.6	8
69	Efficacy of a password-protected pill-dispensing device to enhance disposal of unused opioids after cancer surgery.. Journal of Clinical Oncology, 2021, 39, 264-264.	1.6	1
70	Impact of a hospital specialty pharmacy in partnership with a free-standing care coordination organization on time to delivery and receipt of oral anticancer drugs.. Journal of Clinical Oncology, 2021, 39, 43-43.	1.6	1
71	Effect of healthy diet and exercise on chemotherapy completion rate in women with breast cancer: The Lifestyle, Exercise and Nutrition Early after Diagnosis (LEANer) study: Study protocol for a randomized clinical trial. Contemporary Clinical Trials, 2021, 109, 106508.	1.8	8
72	Hospitalization burden and end-of-life (EOL) care in elderly patients with glioblastoma (GBM).. Journal of Clinical Oncology, 2021, 39, 31-31.	1.6	1

#	ARTICLE	IF	CITATIONS
73	Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography. Breast Cancer Research, 2021, 23, 16.	5.0	2
74	Predictors of Pain Reduction in Trials of Interventions for Aromatase Inhibitor-Associated Musculoskeletal Symptoms. JNCI Cancer Spectrum, 2021, 5, pkab087.	2.9	2
75	Long-term outcomes of vaginal hysterectomy for endometrial cancer. Gynecologic Oncology, 2021, , .	1.4	3
76	Perioperative and persistent opioid utilization following pancreatectomy in the United States. Hpb, 2021, , .	0.3	1
77	Neuronal Protection for Chemotherapy Neuropathy Prevention?. Journal of the National Cancer Institute, 2020, 112, 3-4.	6.3	2
78	Effect of regionalization of endometrial cancer care on site of care and patient travel. American Journal of Obstetrics and Gynecology, 2020, 222, 58.e1-58.e10.	1.3	8
79	Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer. Clinical Breast Cancer, 2020, 20, 80-86.	2.4	22
80	Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307. Journal of the National Cancer Institute, 2020, 112, 698-707.	6.3	48
81	Association between nonadherence to cardiovascular risk factor medications after breast cancer diagnosis and incidence of cardiac events. Cancer, 2020, 126, 1541-1549.	4.1	12
82	Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). Journal of Clinical Oncology, 2020, 38, 804-814.	1.6	142
83	Prospective Study Evaluating Changes in Bone Quality in Premenopausal Women With Breast Cancer Undergoing Adjuvant Chemotherapy. Clinical Breast Cancer, 2020, 20, e327-e333.	2.4	5
84	Patterns of seizure prophylaxis after oncologic neurosurgery. Journal of Neuro-Oncology, 2020, 146, 171-180.	2.9	21
85	Toxicity after adjuvant therapy for stage III uterine cancer. Gynecologic Oncology, 2020, 159, 737-743.	1.4	2
86	Using machine learning to create prognostic systems for endometrial cancer. Gynecologic Oncology, 2020, 159, 744-750.	1.4	23
87	Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. Journal of Clinical Oncology, 2020, 38, 3325-3348.	1.6	457
88	Economic Evaluations in National Cancer Institute-Sponsored Network Cancer Clinical Trials. Value in Health, 2020, 23, 1653-1661.	0.3	2
89	Coronavirus Spectrum Infections (COVID-19, MERS, SARS) in Cancer Patients: A Systematic Review of the Literature. Cancer Investigation, 2020, 38, 436-444.	1.3	5
90	Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies. JNCI Cancer Spectrum, 2020, 4, pkaa034.	2.9	59

#	ARTICLE	IF	CITATIONS
91	Trends in Primary Treatment and Median Survival Among Women With Advanced-Stage Epithelial Ovarian Cancer in the US From 2004 to 2016. JAMA Network Open, 2020, 3, e2017517.	5.9	31
92	The effect of guideline-concordant care in mitigating insurance status disparities in cervical cancer. Gynecologic Oncology, 2020, 159, 309-316.	1.4	16
93	Randomized Trial of Text Messaging to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women With Early-Stage Breast Cancer: SWOG S1105. Journal of Clinical Oncology, 2020, 38, 2122-2129.	1.6	59
94	Association of the Coronavirus Disease 2019 (COVID-19) Outbreak With Enrollment in Cancer Clinical Trials. JAMA Network Open, 2020, 3, e2010651.	5.9	72
95	Design, data linkage, and implementation considerations in the first cooperative group led study assessing financial outcomes in cancer patients and their informal caregivers. Contemporary Clinical Trials, 2020, 95, 106037.	1.8	4
96	Characteristics and outcomes of patients with breast cancer diagnosed with SARS-Cov-2 infection at an academic center in New York City. Breast Cancer Research and Treatment, 2020, 182, 239-242.	2.5	43
97	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet, The, 2020, 395, 1907-1918.	13.7	1,395
98	Travel distance, hospital volume and their association with ovarian cancer short- and long-term outcomes. Gynecologic Oncology, 2020, 158, 415-423.	1.4	8
99	Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting. Journal of Oncology, 2020, 2020, 1-10.	1.3	10
100	ASCO's Quality Care Symposium and the Evolving Science of Value-Based Care. JCO Oncology Practice, 2020, 16, 113-114.	2.9	1
101	Incidence and Predictors of Diabetes Mellitus after a Diagnosis of Early-Stage Breast Cancer in the Elderly Using Real-World Data. Breast Cancer Research and Treatment, 2020, 183, 201-211.	2.5	5
102	Association of Patient Demographic Characteristics and Insurance Status With Survival in Cancer Randomized Clinical Trials With Positive Findings. JAMA Network Open, 2020, 3, e203842.	5.9	29
103	A modern assessment of the surgical pathologic spread and nodal dissemination of endometrial cancer. Gynecologic Oncology, 2020, 157, 329-334.	1.4	4
104	Impact of quality of care on racial disparities in survival for endometrial cancer. American Journal of Obstetrics and Gynecology, 2020, 223, 396.e1-396.e13.	1.3	30
105	Clinical Usefulness of Bright White Light Therapy for Depressive Symptoms in Cancer Survivors: Results from a Series of Personalized (N-of-1) Trials. Healthcare (Switzerland), 2020, 8, 10.	2.0	11
106	Guideline concordant care for prevention of acute chemotherapy-induced nausea and vomiting in children, adolescents, and young adults. Supportive Care in Cancer, 2020, 28, 4761-4769.	2.2	15
107	Oncology Practice During the COVID-19 Pandemic. JAMA - Journal of the American Medical Association, 2020, 323, 2005.	7.4	221
108	Healthcare utilization and cost of care in elderly breast cancer patients enrolled in SWOG clinical trials. Breast Cancer Research and Treatment, 2020, 181, 455-463.	2.5	5



#	ARTICLE	IF	CITATIONS
109	Investigator Use of Social Media for Recruitment of Patients for Cancer Clinical Trials. JAMA Network Open, 2020, 3, e2031202.	5.9	10
110	Risk of cardiovascular disease in women with and without a history of breast cancer: The Pathways Heart Study.. Journal of Clinical Oncology, 2020, 38, 12016-12016.	1.6	3
111	Predictive model of aromatase inhibitor non-adherence using patient-reported outcomes in women with breast cancer (SWOG S1105).. Journal of Clinical Oncology, 2020, 38, 12019-12019.	1.6	3
112	Cumulative incidence of financial hardship in metastatic colorectal cancer (mCRC) patients (pts): Primary endpoint results for SWOG S1417CD.. Journal of Clinical Oncology, 2020, 38, 137-137.	1.6	1
113	Diagnosis of leptomeningeal metastasis (LM) through identification of circulating tumor cells (CTCs) in cerebrospinal fluid (CSF).. Journal of Clinical Oncology, 2020, 38, 3567-3567.	1.6	0
114	Cumulative incidence of financial hardship in metastatic colorectal cancer patients: Primary endpoint results for SWOG S1417CD.. Journal of Clinical Oncology, 2020, 38, 7010-7010.	1.6	8
115	Onset of cardiovascular disease risk factors in women with and without a history of breast cancer: The Pathways Heart Study.. Journal of Clinical Oncology, 2020, 38, 12017-12017.	1.6	0
116	Feasibility of a digital medicine program in optimizing opioid pain control in cancer patients (SWOG) Tj ETQq0 0 0 0 r gBT /Overlock 10 Tf	1.6	0
117	Beyond patient-level barriers: Evaluation of rural residency and area-level deprivation and clinical trial (CT) participation.. Journal of Clinical Oncology, 2020, 38, e19068-e19068.	1.6	0
118	A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013. Journal of Patient-Reported Outcomes, 2020, 4, 54.	1.9	1
119	Opioid prescribing practices in adolescent and young adults with sarcomas.. Journal of Clinical Oncology, 2020, 38, 136-136.	1.6	0
120	The association of patient fatigue and outcomes in advanced cancer: An analysis of four SWOG treatment trials.. Journal of Clinical Oncology, 2020, 38, 140-140.	1.6	0
121	The COVID-19 pandemic impact on breast cancer care delivery at an academic center in New York City.. Journal of Clinical Oncology, 2020, 38, 88-88.	1.6	0
122	“When offered to participate” A systematic review and meta-analysis of patient agreement to participate in cancer clinical trials.. Journal of Clinical Oncology, 2020, 38, 92-92.	1.6	2
123	Trends in obesity among patients registered to SWOG cancer clinical treatment trials.. Journal of Clinical Oncology, 2020, 38, 126-126.	1.6	0
124	Sequencing of therapy in women with stage III endometrial carcinoma receiving adjuvant combination chemotherapy and radiation. Gynecologic Oncology, 2019, 155, 13-20.	1.4	11
125	Factors Associated with Multidisciplinary Consultations in Patients with Early Stage Breast Cancer. Cancer Investigation, 2019, 37, 233-241.	1.3	8
126	Use of fertility preservation services in female reproductive-aged cancer patients. American Journal of Obstetrics and Gynecology, 2019, 221, 328.e1-328.e16.	1.3	21



#	ARTICLE	IF	CITATIONS
127	Safety of same-day discharge for minimally invasive hysterectomy for endometrial cancer. American Journal of Obstetrics and Gynecology, 2019, 221, 239.e1-239.e11.	1.3	15
128	Osteoporosis in colorectal cancer survivors: analysis of the linkage between SWOG trial enrollees and Medicare claims. Archives of Osteoporosis, 2019, 14, 83.	2.4	5
129	Use of Bevacizumab for Elderly Patients With Stage IV Colon Cancer: Analysis of SEER-Medicare Data. Clinical Colorectal Cancer, 2019, 18, e294-e299.	2.3	5
130	A comparison of nurses' and physicians' perception of cancer treatment burden based on reported adverse events. Health and Quality of Life Outcomes, 2019, 17, 146.	2.4	2
131	Neuroendocrine carcinoma of the endometrium: Disease course, treatment, and outcomes. Gynecologic Oncology, 2019, 155, 254-261.	1.4	15
132	Quality of Care and Outcomes of Patients With Gynecologic Malignancies Treated at Safety-Net Hospitals. JNCI Cancer Spectrum, 2019, 3, pkz039.	2.9	8
133	Dynamic Vascular Optical Tomographic Imaging for Peripheral Artery Disease and Breast Cancer. , 2019, , 353-400.		4
134	Regionalization of care for women with ovarian cancer. Gynecologic Oncology, 2019, 154, 394-400.	1.4	6
135	Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812). Cancer Prevention Research, 2019, 12, 481-490.	1.5	14
136	FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data. Clinical Colorectal Cancer, 2019, 18, 133-140.	2.3	44
137	Association between body mass index and response to duloxetine for aromatase inhibitor-associated musculoskeletal symptoms in SWOG S1202. Cancer, 2019, 125, 2123-2129.	4.1	18
138	Development and validation of a risk-calculator for adverse perioperative outcomes for women with ovarian cancer. American Journal of Obstetrics and Gynecology, 2019, 220, 571.e1-571.e8.	1.3	29
139	Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation. Journal of the National Cancer Institute, 2019, 111, 245-255.	6.3	294
140	Association of National Cancer Institute-Sponsored Clinical Trial Network Group Studies With Guideline Care and New Drug Indications. JAMA Network Open, 2019, 2, e1910593.	5.9	18
141	Use and Misuse of Opioids After Gynecologic Surgical Procedures. Obstetrics and Gynecology, 2019, 134, 250-260.	2.4	46
142	Utility of preoperative breast MRI in patient selection for accelerated partial breast irradiation by different consensus guidelines. Breast Journal, 2019, 25, 160-162.	1.0	1
143	Obesity-associated Breast Inflammation among Hispanic/Latina Breast Cancer Patients. Cancer Prevention Research, 2019, 12, 21-30.	1.5	9
144	Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices. JAMA Oncology, 2019, 5, 497.	7.1	67

#	ARTICLE	IF	CITATIONS
145	Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation. JAMA Oncology, 2019, 5, 326.	7.1	115
146	A randomized trial of interpersonal psychotherapy, problem solving therapy, and supportive therapy for major depressive disorder in women with breast cancer. Breast Cancer Research and Treatment, 2019, 173, 353-364.	2.5	21
147	Osteonecrosis of the jaw in patients with cancer receiving zoledronic acid for bone metastases: SWOG S0702, NCT00874211.. Journal of Clinical Oncology, 2019, 37, 11502-11502.	1.6	4
148	Sex differences in adverse event reporting in SWOG chemotherapy, biologic/immunotherapy, and targeted agent cancer clinical trials.. Journal of Clinical Oncology, 2019, 37, 11588-11588.	1.6	5
149	The effect of metformin on sex hormones in non-diabetic breast cancer patients in CCTG MA.32: A Phase III randomized adjuvant trial of metformin versus placebo in addition to standard therapy.. Journal of Clinical Oncology, 2019, 37, 529-529.	1.6	3
150	Randomized trial of text messaging (TM) to reduce early discontinuation of aromatase inhibitor (AI) therapy in women with breast cancer: SWOG S1105.. Journal of Clinical Oncology, 2019, 37, 6516-6516.	1.6	6
151	Delay in receipt of newly prescribed oral anticancer drugs.. Journal of Clinical Oncology, 2019, 37, 6541-6541.	1.6	3
152	Design and accrual of S1417CD: Development of a prospective financial impact assessment tool in patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2019, 37, TPS6652-TPS6652.	1.6	1
153	Use of nonclinical staff to coordinate oral anticancer drug prescriptions.. Journal of Clinical Oncology, 2019, 37, 72-72.	1.6	1
154	Diffuse optical tomography of the breast: a potential modifiable biomarker of breast cancer risk with neoadjuvant chemotherapy. Biomedical Optics Express, 2019, 10, 4305.	2.9	9
155	Hypertension and use of bevacizumab among patients treated in community settings.. Journal of Clinical Oncology, 2019, 37, e18279-e18279.	1.6	0
156	The impact of NCI-sponsored network group clinical trials on guideline care and new drug indications.. Journal of Clinical Oncology, 2019, 37, 6604-6604.	1.6	0
157	Factors associated with over and underuse of response evaluation in elderly myeloma patients.. Journal of Clinical Oncology, 2019, 37, e19518-e19518.	1.6	0
158	A randomized trial of a healthy lifestyle intervention versus usual care on chemotherapy and endocrine therapy adherence rate in women with breast cancer: The Lifestyle Exercise and Nutrition Early After Diagnosis (LEANER) Study.. Journal of Clinical Oncology, 2019, 37, TPS11633-TPS11633.	1.6	1
159	Socioeconomic deprivation and cancer outcomes in patients treated in clinical trials.. Journal of Clinical Oncology, 2019, 37, 162-162.	1.6	1
160	Patients enrolled in clinical trials with Medicaid or no insurance and overall survival benefits from new interventions.. Journal of Clinical Oncology, 2019, 37, 119-119.	1.6	0
161	Adherence to clinical practice guidelines for the prevention of acute chemotherapy-induced nausea and vomiting in children, adolescents, and young adults with cancer receiving their first cycle of highly emetogenic chemotherapy.. Journal of Clinical Oncology, 2019, 37, 19-19.	1.6	1
162	Comparison of attitudes and beliefs about cancer clinical trial enrollment between physicians, research staff, and cancer patients.. Journal of Clinical Oncology, 2019, 37, 170-170.	1.6	2

#	ARTICLE	IF	CITATIONS
163	A standardized workflow to improve the consent process among patients initiating an oral anticancer drug.. Journal of Clinical Oncology, 2019, 37, 259-259.	1.6	12
164	Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system. Breast Cancer Research and Treatment, 2018, 170, 623-631.	2.5	26
165	Dynamic Diffuse Optical Tomography for Monitoring Neoadjuvant Chemotherapy in Patients with Breast Cancer. Radiology, 2018, 287, 778-786.	7.3	39
166	Survival by Hispanic ethnicity among patients with cancer participating in SWOG clinical trials. Cancer, 2018, 124, 1760-1769.	4.1	9
167	Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715). Journal of the National Cancer Institute, 2018, 110, 669-676.	6.3	55
168	Racial disparities in young women with endometrial cancer. Gynecologic Oncology, 2018, 148, 527-534.	1.4	34
169	Trends in Sentinel Lymph Node Mapping and Adjuvant Therapy in Endometrial Carcinoma. Cancer Investigation, 2018, 36, 190-198.	1.3	13
170	Impact of hospital volume on racial disparities and outcomes for endometrial cancer. Gynecologic Oncology, 2018, 149, 329-336.	1.4	14
171	Identifying modifiable and non-modifiable risk factors associated with prolonged length of stay after hysterectomy for uterine cancer. Gynecologic Oncology, 2018, 149, 545-553.	1.4	3
172	Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial. Journal of the National Cancer Institute, 2018, 110, 1208-1215.	6.3	16
173	Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence. Gynecologic Oncology, 2018, 148, 19-27.	1.4	15
174	Association Between Hospital Financial Distress and Immediate Breast Reconstruction Surgery After Mastectomy Among Women With Ductal Carcinoma In Situ. JAMA Surgery, 2018, 153, 344.	4.3	8
175	Estimating global treatment toxicity burden from adverseâ€event data. Cancer, 2018, 124, 858-864.	4.1	7
176	Failure to Rescue and Mortality Following Resection of Intracranial Neoplasms. Neurosurgery, 2018, 83, 263-269.	1.1	14
177	National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer. Journal of Clinical Oncology, 2018, 36, 3259-3268.	1.6	19
178	Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials. Journal of Clinical Oncology, 2018, 36, 2710-2717.	1.6	61
179	Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline. Journal of Clinical Oncology, 2018, 36, 2647-2655.	1.6	262
180	Extent of Exclusions for Chronic Conditions in Breast Cancer Trials. JNCI Cancer Spectrum, 2018, 2, pky059.	2.9	8

#	ARTICLE	IF	CITATIONS
181	Acupuncture for Aromatase Inhibitor-Related Joint Pain Among Breast Cancer Patients. JAMA - Journal of the American Medical Association, 2018, 320, 2270.	7.4	9
182	Phase II Feasibility Study of a Weight Loss Intervention in Female Breast and Colorectal Cancer Survivors (SWOG S1008). Obesity, 2018, 26, 1539-1549.	3.0	5
183	Use and outcomes of minimally invasive hysterectomy for women with nonendometrioid endometrial cancers. American Journal of Obstetrics and Gynecology, 2018, 219, 463.e1-463.e12.	1.3	14
184	Adherence to colonoscopy at 1 year following resection of localized colon cancer: a retrospective cohort study. Therapeutic Advances in Gastroenterology, 2018, 11, 175628481876592.	3.2	8
185	Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927). Breast Cancer Research and Treatment, 2018, 172, 603-610.	2.5	37
186	Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. Journal of Clinical Oncology, 2018, 36, 326-332.	1.6	79
187	Assessment of Electronic Alert to Reduce Overuse of Granulocyte Colony-Stimulating Factor in Patients Hospitalized for Febrile Neutropenia. JAMA Oncology, 2018, 4, 996.	7.1	2
188	Characteristics associated with prolonged length of stay after hysterectomy for benign gynecologic conditions. American Journal of Obstetrics and Gynecology, 2018, 219, 89.e1-89.e15.	1.3	20
189	The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials. Cancer Epidemiology, 2018, 55, 117-122.	1.9	3
190	Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer. JAMA - Journal of the American Medical Association, 2018, 320, 167.	7.4	202
191	Geographic Distribution and Survival Outcomes for Rural Patients With Cancer Treated in Clinical Trials. JAMA Network Open, 2018, 1, e181235.	5.9	130
192	A New Framework for Patient Engagement in Cancer Clinical Trials Cooperative Group Studies. Journal of the National Cancer Institute, 2018, 110, 553-559.	6.3	36
193	Utilization of ovarian transposition for fertility preservation among young women with pelvic malignancies who undergo radiotherapy. American Journal of Obstetrics and Gynecology, 2018, 219, 415-417.	1.3	10
194	Phase IB trial of ACY-1215 (Ricolinostat) combined with nab-paclitaxel in metastatic breast cancer.. Journal of Clinical Oncology, 2018, 36, 1058-1058.	1.6	1
195	CA15-3/MUC1 in CCTG MA-32 (NCT01101438): A phase III RCT of the effect of metformin vs. placebo on invasive disease free and overall survival in early stage breast cancer (BC).. Journal of Clinical Oncology, 2018, 36, 557-557.	1.6	2
196	Geographic distribution and survival outcomes for rural cancer patients treated in clinical trials.. Journal of Clinical Oncology, 2018, 36, 6569-6569.	1.6	4
197	Factors associated with non-adherence to lenalidomide in patients with multiple myeloma.. Journal of Clinical Oncology, 2018, 36, e20031-e20031.	1.6	3
198	The Breast Cancer Weight Loss (BWEL) trial: Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early-stage breast cancer (Alliance) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5		

#	ARTICLE	IF	CITATIONS
199	Patient comorbid conditions and cancer clinical trial participation.. Journal of Clinical Oncology, 2018, 36, 6540-6540.	1.6	1
200	Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927).. Journal of Clinical Oncology, 2018, 36, 10000-10000.	1.6	0
201	Prevalence of HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) among newly diagnosed cancer patients treated in academic and community oncology practices: SWOG S1204.. Journal of Clinical Oncology, 2018, 36, 6600-6600.	1.6	0
202	Factors associated with follow-up physician visits among women with early stage breast cancer.. Journal of Clinical Oncology, 2018, 36, 6531-6531.	1.6	0
203	Impact of clinic characteristics on the adoption of a guideline-based standing order algorithm and patient accrual in the pragmatic cluster-randomized trial SWOG S1415CD (NCT02728596).. Journal of Clinical Oncology, 2018, 36, 60-60.	1.6	0
204	From A to Xeloda: Practical considerations for implementing a chemotherapy regimen ordering system intervention.. Journal of Clinical Oncology, 2018, 36, 57-57.	1.6	0
205	The influence of patient engagement on the design and implementation of a clinical trial to improve cancer care delivery.. Journal of Clinical Oncology, 2018, 36, 223-223.	1.6	1
206	Implementing an EHR guidelineâ€‘based intervention in paper ordering systems.. Journal of Clinical Oncology, 2018, 36, 56-56.	1.6	0
207	Barriers to Recruitment and Adherence in a Randomized Controlled Diet and Exercise Weight Loss Intervention Among Minority Breast Cancer Survivors. Journal of Immigrant and Minority Health, 2017, 19, 120-129.	1.6	36
208	Utilization of sentinel lymph node biopsy for uterine cancer. American Journal of Obstetrics and Gynecology, 2017, 216, 594.e1-594.e13.	1.3	25
209	Disparities in the management of ectopic pregnancy. American Journal of Obstetrics and Gynecology, 2017, 217, 49.e1-49.e10.	1.3	38
210	Factors and Costs Associated With Delay in Treatment Initiation and Prolonged Length of Stay With Inpatient EPOCH Chemotherapy in Patients With Hematologic Malignancies. Cancer Investigation, 2017, 35, 202-214.	1.3	7
211	Diffuse optical tomography changes correlate with residual cancer burden after neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Research and Treatment, 2017, 162, 533-540.	2.5	15
212	Scalp Cooling to Prevent Chemotherapy-Induced Alopecia. JAMA - Journal of the American Medical Association, 2017, 317, 587.	7.4	11
213	Patterns and reasons for switching classes of hormonal therapy among women with early-stage breast cancer. Cancer Causes and Control, 2017, 28, 557-562.	1.8	22
214	Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32. Breast Cancer Research and Treatment, 2017, 164, 371-378.	2.5	9
215	How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention?. Npj Breast Cancer, 2017, 3, 20.	5.2	33
216	Utility of radiation therapy for early-stage uterine papillary serous carcinoma. Gynecologic Oncology, 2017, 145, 269-276.	1.4	27

#	ARTICLE	IF	CITATIONS
217	Utilization of gynecologic services in women with breast cancer receiving hormonal therapy. American Journal of Obstetrics and Gynecology, 2017, 217, 59.e1-59.e12.	1.3	8
218	Association between Body Mass Index and Cancer Survival in a Pooled Analysis of 22 Clinical Trials. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 21-29.	2.5	124
219	Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design. Npj Breast Cancer, 2017, 3, 37.	5.2	84
220	All-cause mortality in young women with endometrial cancer receiving progesterone therapy. American Journal of Obstetrics and Gynecology, 2017, 217, 669.e1-669.e13.	1.3	27
221	Trends in end-of-life care and health care spending in women with uterine cancer. American Journal of Obstetrics and Gynecology, 2017, 217, 434.e1-434.e10.	1.3	17
222	Association between survival time with metastatic breast cancer and aggressive end-of-life care. Breast Cancer Research and Treatment, 2017, 166, 549-558.	2.5	22
223	Using Delayed Toxicities to Re-evaluate Tolerability in Phase 2 Trials: A Case Example using Bortezomib. Cancer Investigation, 2017, 35, 484-489.	1.3	2
224	A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: the TrACER study. Journal of Comparative Effectiveness Research, 2017, 6, 461-470.	1.4	13
225	BMI, Lifestyle Factors and Taxane-Induced Neuropathy in Breast Cancer Patients: The Pathways Study. Journal of the National Cancer Institute, 2017, 109, djw206.	6.3	86
226	Comparative Effectiveness of Cancer Control and Survival after Robot-Assisted versus Open Radical Prostatectomy. Journal of Urology, 2017, 197, 115-121.	0.4	49
227	American Society of Clinical Oncology Summit on Addressing Obesity Through Multidisciplinary Provider Collaboration: Key Findings and Recommendations for Action. Obesity, 2017, 25, S34-S39.	3.0	12
228	Understanding Breast Cancer Knowledge and Barriers to Treatment Adherence: A Qualitative Study Among Breast Cancer Survivors. BioResearch Open Access, 2017, 6, 159-168.	2.6	10
229	History of Diabetes and Survival Outcome Among Participants 65 Years or Older in SWOG Clinical Trials. JCO Clinical Cancer Informatics, 2017, 1, 1-12.	2.1	1
230	A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer.. Journal of Clinical Oncology, 2017, 35, TPS1112-TPS1112.	1.6	4
231	Social support at diagnosis and noninitiation, discontinuation, and nonadherence to adjuvant hormonal therapy in the Pathways Study.. Journal of Clinical Oncology, 2017, 35, 7-7.	1.6	1
232	Factors associated with neurokinin-1 receptor antagonist use among commercially insured cancer patients receiving highly emetogenic chemotherapy.. Journal of Clinical Oncology, 2017, 35, 24-24.	1.6	0
233	Complementary and alternative medicine use and hormonal therapy initiation in women with hormone receptor-positive breast cancer: The BQUAL study.. Journal of Clinical Oncology, 2017, 35, e13097-e13097.	1.6	0
234	NCI Breast Cancer Steering Committee Working Group (WG) report on meaningful and appropriate endpoints for clinical trials (CT) in metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2017, 35, 1073-1073.	1.6	0



#	ARTICLE	IF	CITATIONS
235	Patterns of osteoporosis (OP) in survivors of colorectal cancer (CRC) enrolled on SWOG trials.. Journal of Clinical Oncology, 2017, 35, 10056-10056.	1.6	0
236	The scientific impact and value of large, NCI-sponsored randomized phase III cancer prevention trials.. Journal of Clinical Oncology, 2017, 35, 1541-1541.	1.6	0
237	Differences in global toxicity burden among patients and care providers during initial chemotherapy for breast cancer.. Journal of Clinical Oncology, 2017, 35, e21649-e21649.	1.6	0
238	Two-year trends of taxane-induced neuropathy in women enrolled in a randomized trial of acetyl-L-carnitine (SWOG S0715).. Journal of Clinical Oncology, 2017, 35, 10093-10093.	1.6	0
239	Axillary evaluation and lymphedema in women with ductal carcinoma in situ. Breast Cancer Research and Treatment, 2016, 158, 373-384.	2.5	14
240	Reply to F. Dayyani et al. Journal of Oncology Practice, 2016, 12, 277-277.	2.5	0
241	Sticking to It: Improving Outcomes by Increasing Adherence. Journal of Clinical Oncology, 2016, 34, 2440-2442.	1.6	16
242	Abdominal vs Minimally Invasive Hysterectomyâ€”Reply. JAMA - Journal of the American Medical Association, 2016, 316, 2677.	7.4	0
243	Nonadherence to Oral Medications for Chronic Conditions in Breast Cancer Survivors. Journal of Oncology Practice, 2016, 12, e800-e809.	2.5	30
244	Complementary and alternative medicine use among US cancer survivors. Journal of Cancer Survivorship, 2016, 10, 850-864.	2.9	79
245	Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer. Breast Cancer Research and Treatment, 2016, 156, 453-464.	2.5	89
246	Adverse Health Effects of Intermittent vs Continuous Androgen Deprivation Therapy for Metastatic Prostate Cancerâ€”Reply. JAMA Oncology, 2016, 2, 686.	7.1	0
247	Association Between Geographic Access to Cancer Care and Receipt of Radiation Therapy forÂRectal Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 94, 719-728.	0.8	78
248	Use and Costs of Disease Monitoring in Women With Metastatic Breast Cancer. Journal of Clinical Oncology, 2016, 34, 2820-2826.	1.6	28
249	Safety, Utilization, and Cost of Image-Guided Percutaneous Liver Biopsy Among Cancer Patients. Cancer Investigation, 2016, 34, 189-196.	1.3	9
250	Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL). Breast Cancer Research and Treatment, 2016, 157, 133-143.	2.5	51
251	Prescription of extended-duration thromboprophylaxis after high-risk, abdominopelvic cancer surgery. Gynecologic Oncology, 2016, 141, 531-537.	1.4	20
252	Survivorship care plans and adherence to lifestyle recommendations among breast cancer survivors. Journal of Cancer Survivorship, 2016, 10, 956-963.	2.9	41



#	ARTICLE	IF	CITATIONS
253	Association Between Complementary and Alternative Medicine Use and Breast Cancer Chemotherapy Initiation. JAMA Oncology, 2016, 2, 1170.	7.1	59
254	Reply. American Journal of Obstetrics and Gynecology, 2016, 215, 134-135.	1.3	0
255	Trends in Use and Outcomes of Women Undergoing Hysterectomy With Electric Power Morcellation. JAMA - Journal of the American Medical Association, 2016, 316, 877.	7.4	41
256	Long-term Diet and Biomarker Changes after a Short-term Intervention among Hispanic Breast Cancer Survivors: The <i>Cocinar Para Su Salud!</i> Randomized Controlled Trial. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1491-1502.	2.5	33
257	Predictors of Interventional Treatment Use for Venous Thromboembolism in Cancer Patients. Cancer Investigation, 2016, 34, 408-414.	1.3	1
258	Do Surgeons or Does Hospital Economics Ultimately Decide Operative Approach?â€”Reply. JAMA Surgery, 2016, 151, 884.	4.3	1
259	Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. Journal of Clinical Oncology, 2016, 34, 3014-3022.	1.6	170
260	Nonadherence to Medications for Chronic Conditions and Nonadherence to Adjuvant Hormonal Therapy in Women With Breast Cancer. JAMA Oncology, 2016, 2, 1326.	7.1	64
261	A prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: the breast cancer quality of careÂ®study (BQUAL). Breast Cancer Research and Treatment, 2016, 158, 127-138.	2.5	16
262	Magnitude of risk for nodal metastasis associated with lymphovascular space invasion for endometrial cancer. Gynecologic Oncology, 2016, 140, 387-393.	1.4	52
263	Radiation Duration in Women with Cervical Cancer Treated with Primary Chemoradiation: A Population-Based Analysis. Cancer Investigation, 2016, 34, 137-147.	1.3	16
264	Natural history and outcome of neuroendocrine carcinoma of the cervix. Gynecologic Oncology, 2016, 141, 247-254.	1.4	72
265	Effect of Regional Hospital Competition and Hospital Financial Status on the Use of Robotic-Assisted Surgery. JAMA Surgery, 2016, 151, 612.	4.3	86
266	Comparative Effectiveness of Minimally Invasive Hysterectomy for Endometrial Cancer. Journal of Clinical Oncology, 2016, 34, 1087-1096.	1.6	83
267	Underuse of BRCA testing in patients with breast and ovarian cancer. American Journal of Obstetrics and Gynecology, 2016, 214, 761-763.	1.3	31
268	Overuse of external beam radiotherapy for stage I endometrial cancer. American Journal of Obstetrics and Gynecology, 2016, 215, 75.e1-75.e7.	1.3	6
269	Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer. JAMA Oncology, 2016, 2, 453.	7.1	83
270	National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons. Supportive Care in Cancer, 2016, 24, 1439-1447.	2.2	86

#	ARTICLE	IF	CITATIONS
271	Body mass index, lifestyle factors, and taxane-induced neuropathy in women with breast cancer: The Pathways study.. Journal of Clinical Oncology, 2016, 34, 10002-10002.	1.6	1
272	Understanding efficiency of chemotherapy delivery for planned chemotherapy admission at Columbia University Medical Center.. Journal of Clinical Oncology, 2016, 34, 206-206.	1.6	0
273	Impact of weight loss and exercise on VEGF levels in breast cancer survivors.. Journal of Clinical Oncology, 2016, 34, 10103-10103.	1.6	1
274	Diffusion of abiraterone use in prostate cancer patients.. Journal of Clinical Oncology, 2016, 34, e18062-e18062.	1.6	1
275	Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants in SWOG clinical trials.. Journal of Clinical Oncology, 2016, 34, 10001-10001.	1.6	0
276	Comparison of physicians, nurses' and patients' assessment of overall symptom burden.. Journal of Clinical Oncology, 2016, 34, e18123-e18123.	1.6	0
277	Randomized trial of medroxyprogesterone acetate for prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630.. Journal of Clinical Oncology, 2016, 34, 547-547.	1.6	0
278	Randomized Exercise Trial of Aromatase Inhibitorâ€“Induced Arthralgia in Breast Cancer Survivors. Journal of Clinical Oncology, 2015, 33, 1104-1111.	1.6	249
279	Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ. Breast Journal, 2015, 21, 377-386.	1.0	34
280	Identifying Predictors of Taxane-Induced Peripheral Neuropathy Using Mass Spectrometry-Based Proteomics Technology. PLoS ONE, 2015, 10, e0145816.	2.5	28
281	Effect of Metformin vs Placebo on and Metabolic Factors in NCIC CTG MA.32. Journal of the National Cancer Institute, 2015, 107, djv006-djv006.	6.3	112
282	Complications Following Stereotactic Needle Biopsy of Intracranial Tumors. World Neurosurgery, 2015, 84, 1084-1089.	1.3	112
283	Risk stratification and outcomes of women undergoing surgery for ovarian cancer. Gynecologic Oncology, 2015, 138, 62-69.	1.4	41
284	Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitorâ€“Induced Musculoskeletal Pain: SWOG S0927. Journal of Clinical Oncology, 2015, 33, 1910-1917.	1.6	83
285	Economic and Survival Implications of Use of Electric Power Morcellation for Hysterectomy for Presumed Benign Gynecologic Disease. Journal of the National Cancer Institute, 2015, 107, djv251.	6.3	14
286	Use of Electric Power Morcellation and Prevalence of Underlying Cancer in Women Who Undergo Myomectomy. JAMA Oncology, 2015, 1, 69.	7.1	65
287	Reply to L. Gianni et al. Journal of Clinical Oncology, 2015, 33, 4312-4312.	1.6	0
288	Influence of treatment center and hospital volume on survival for locally advanced cervical cancer. Gynecologic Oncology, 2015, 139, 506-512.	1.4	51

#	ARTICLE	IF	CITATIONS
289	High versus low-dose rate brachytherapy for cervical cancer. <i>Gynecologic Oncology</i> , 2015, 136, 534-541.	1.4	24
290	Dietary Modifications, Weight Loss, and Changes in Metabolic Markers Affect Global DNA Methylation in Hispanic, African American, and Afro-Caribbean Breast Cancer Survivors,. <i>Journal of Nutrition</i> , 2015, 145, 783-790.	2.9	59
291	Perfecting Breast-Cancer Treatment “ Incremental Gains and Musculoskeletal Pains. <i>New England Journal of Medicine</i> , 2015, 372, 477-478.	27.0	14
292	The Diffusion of Docetaxel in Patients With Metastatic Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	17
293	Trends in Use and Safety of Image-Guided Transthoracic Needle Biopsies in Patients With Cancer. <i>Journal of Oncology Practice</i> , 2015, 11, e351-e359.	2.5	25
294	The Influence of Hospital and Surgeon Factors on the Prevalence of Axillary Lymph Node Evaluation in Ductal Carcinoma In Situ. <i>JAMA Oncology</i> , 2015, 1, 323.	7.1	26
295	Relationship Between Surgical Oncologic Outcomes and Publically Reported Hospital Quality and Satisfaction Measures. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	15
296	Food environments are relevant to recruitment and adherence in dietary modification trials. <i>Nutrition Research</i> , 2015, 35, 480-488.	2.9	9
297	Household Net Worth, Racial Disparities, and Hormonal Therapy Adherence Among Women With Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1053-1059.	1.6	102
298	Quality of Care, Including Survivorship Care Plans. <i>Advances in Experimental Medicine and Biology</i> , 2015, 862, 255-269.	1.6	6
299	Long-term mortality among women with epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 138, 421-428.	1.4	54
300	Methods to Standardize a Multicenter Acupuncture Trial Protocol to Reduce Aromatase Inhibitor-related Joint Symptoms in Breast Cancer Patients. <i>JAMS Journal of Acupuncture and Meridian Studies</i> , 2015, 8, 152-158.	0.7	10
301	Use and duration of chemotherapy and its impact on survival in early-stage ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 137, 203-209.	1.4	16
302	Barriers and Facilitators to Recruitment to a Culturally Based Dietary Intervention Among Urban Hispanic Breast Cancer Survivors. <i>Journal of Racial and Ethnic Health Disparities</i> , 2015, 2, 244-255.	3.2	18
303	Association Between Geographic Access to Cancer Care, Insurance, and Receipt of Chemotherapy: Geographic Distribution of Oncologists and Travel Distance. <i>Journal of Clinical Oncology</i> , 2015, 33, 3177-3185.	1.6	187
304	Population-level trends in relative survival for cervical cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 213, 670.e1-670.e7.	1.3	39
305	Recommendations for Obesity Clinical Trials in Cancer Survivors: American Society of Clinical Oncology Statement. <i>Journal of Clinical Oncology</i> , 2015, 33, 3961-3967.	1.6	50
306	Vitamin D-related gene polymorphisms, plasma 25-hydroxyvitamin D, and breast cancer risk. <i>Cancer Causes and Control</i> , 2015, 26, 187-203.	1.8	60

#	ARTICLE	IF	CITATIONS
307	Symptoms: Aromatase Inhibitor Induced Arthralgias. <i>Advances in Experimental Medicine and Biology</i> , 2015, 862, 89-100.	1.6	16
308	Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307.. <i>Journal of Clinical Oncology</i> , 2015, 33, 503-503.	1.6	16
309	Phase II feasibility study of a physical activity and dietary change weight loss intervention in a subset analysis of breast cancer survivors (SWOG S1008).. <i>Journal of Clinical Oncology</i> , 2015, 33, 9572-9572.	1.6	1
310	Symptom clusters in patients with advanced prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20647-e20647.	1.6	2
311	Identifying predictors of taxane-induced peripheral neuropathy using shotgun proteomics technology.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9607-9607.	1.6	0
312	Long-term consequences of intermittent and continuous androgen deprivation in older patients with metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5008-5008.	1.6	0
313	The influence of hospital and surgeon factors on the prevalence of axillary evaluation in ductal carcinoma in situ.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6529-6529.	1.6	0
314	Serum tumor marker utilization in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6599-6599.	1.6	0
315	Randomized sham controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20738-e20738.	1.6	0
316	Association between geographic access to cancer care and receipt of chemotherapy: Geographic distribution of oncologists and travel distance.. <i>Journal of Clinical Oncology</i> , 2015, 33, e17561-e17561.	1.6	0
317	Presurgical Trial of Metformin in Overweight and Obese Patients with Newly Diagnosed Breast Cancer. <i>Cancer Investigation</i> , 2014, 32, 150-157.	1.3	66
318	Erythropoiesis-Stimulating Agent Use After Changes in Medicare Reimbursement Policies. <i>Journal of Oncology Practice</i> , 2014, 10, 264-269.	2.5	11
319	American Society of Clinical Oncology Position Statement on Obesity and Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3568-3574.	1.6	418
320	The Change From Brand-Name to Generic Aromatase Inhibitors and Hormone Therapy Adherence for Early-Stage Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	85
321	Uterine Pathology in Women Undergoing Minimally Invasive Hysterectomy Using Morcellation. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1253.	7.4	132
322	Measure for Measure: The Cost of Improving Quality. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	2
323	Comparison of Survival Outcomes Among Cancer Patients Treated In and Out of Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju002.	6.3	178
324	Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. <i>Lancet Oncology</i> , The, 2014, 15, 474-482.	10.7	45

#	ARTICLE	IF	CITATIONS
325	Safety and Tolerance of Radical Hysterectomy for Cervical Cancer in the Elderly. Gynecologic Oncology, 2014, 134, 36-41.	1.4	24
326	Clinical Practice Guidelines on the Use of Integrative Therapies as Supportive Care in Patients Treated for Breast Cancer. Journal of the National Cancer Institute Monographs, 2014, 2014, 346-358.	2.1	207
327	Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2014, 32, 1941-1967.	1.6	976
328	Presurgical evaluation of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer.. Journal of Clinical Oncology, 2014, 32, 2613-2613.	1.6	3
329	SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: Comparison of toxicities and patient-stated preference for oral versus intravenous delivery.. Journal of Clinical Oncology, 2014, 32, 558-558.	1.6	12
330	Omega-3 fatty acids for aromatase inhibitorâ€œinduced musculoskeletal symptoms in women with early-stage breast cancer (SWOG S0927).. Journal of Clinical Oncology, 2014, 32, 9532-9532.	1.6	2
331	A multicenter phase II study of docosahexaenoic acid (DHA) in patients (pts) with a history of breast cancer (BC), premalignant lesions, or benign breast disease.. Journal of Clinical Oncology, 2014, 32, TPS1615-TPS1615.	1.6	2
332	Bone Health History in Breast Cancer Patients on Aromatase Inhibitors. PLoS ONE, 2014, 9, e111477.	2.5	15
333	Vitamin B12 (Vit B12) biochemical (BCH) deficiency (DEF) in non-diabetic breast cancer (BC) patients on NCIC CTG MA.32: A phase III randomized adjuvant BC trial comparing metformin (Met) to placebo (Pl).. Journal of Clinical Oncology, 2014, 32, 542-542.	1.6	1
334	Correlation between risk benefit index and uptake of breast cancer chemoprevention.. Journal of Clinical Oncology, 2014, 32, 1568-1568.	1.6	0
335	Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2-positive breast cancer.. Journal of Clinical Oncology, 2014, 32, TPS666-TPS666.	1.6	0
336	Relationship between surgical oncologic outcomes and publically reported hospital quality measures.. Journal of Clinical Oncology, 2014, 32, 6504-6504.	1.6	0
337	Prolonged radiation duration in women with cervical cancer: A population-based analysis of associated factors and impact on survival.. Journal of Clinical Oncology, 2014, 32, 6518-6518.	1.6	0
338	Looking beyond the first cycle in phase I cancer clinical trials.. Journal of Clinical Oncology, 2014, 32, 6587-6587.	1.6	0
339	Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer. Supportive Care in Cancer, 2013, 21, 1077-1087.	2.2	46
340	Randomized controlled trial of a clinic-based survivorship intervention following adjuvant therapy in breast cancer survivors. Breast Cancer Research and Treatment, 2013, 138, 795-806.	2.5	104
341	Supplement use during an intergroup clinical trial for breast cancer (S0221). Breast Cancer Research and Treatment, 2013, 137, 903-913.	2.5	31
342	Randomized Double-Blind Placebo-Controlled Trial of Acetyl-L-Carnitine for the Prevention of Taxane-Induced Neuropathy in Women Undergoing Adjuvant Breast Cancer Therapy. Journal of Clinical Oncology, 2013, 31, 2627-2633.	1.6	184

#	ARTICLE	IF	CITATIONS
343	Contraindicated Use of Bevacizumab and Toxicity in Elderly Patients With Cancer. Journal of Clinical Oncology, 2013, 31, 3592-3599.	1.6	48
344	Patient Income Level and Cancer Clinical Trial Participation. Journal of Clinical Oncology, 2013, 31, 536-542.	1.6	209
345	Optical biomarkers for breast cancer derived from dynamic diffuse optical tomography. Journal of Biomedical Optics, 2013, 18, 096012.	2.6	60
346	Disparities and Challenges in Adherence to Oral Antineoplastic Agents. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 271-276.	3.8	21
347	Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer (BC).. Journal of Clinical Oncology, 2013, 31, 1033-1033.	1.6	3
348	Uptake and patterns of use of gemcitabine for stage IV pancreatic cancer.. Journal of Clinical Oncology, 2013, 31, e15074-e15074.	1.6	0
349	Ethnic differences in tumor proliferation in women with early-stage breast cancer.. Journal of Clinical Oncology, 2013, 31, 560-560.	1.6	0
350	Dose-dependent pharmacokinetic (PK) interaction of pegylated liposomal doxorubicin (PLD) with escalating doses of veliparib in a phase I study.. Journal of Clinical Oncology, 2013, 31, 2591-2591.	1.6	1
351	Reply to S. Sukumar et al. Journal of Clinical Oncology, 2012, 30, 2932-2933.	1.6	0
352	Uptake and Economic Impact of First-Cycle Colony-Stimulating Factor Use During Adjuvant Treatment of Breast Cancer. Journal of Clinical Oncology, 2012, 30, 806-812.	1.6	27
353	Comparative Effectiveness Research in Oncology Methodology: Observational Data. Journal of Clinical Oncology, 2012, 30, 4215-4222.	1.6	129
354	Use of a Urine Anastrozole Assay to Determine Treatment Discontinuation Among Women With Hormone-Sensitive Breast Cancer: A Pilot Study. Journal of Oncology Practice, 2012, 8, e100-e104.	2.5	8
355	Mutational analysis of circulating tumor cells in breast cancer patients by targeted clonal sequencing.. Journal of Clinical Oncology, 2012, 30, 10516-10516.	1.6	1
356	SWOG S0715: Randomized placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy during adjuvant breast cancer therapy.. Journal of Clinical Oncology, 2012, 30, 9018-9018.	1.6	3
357	Aromatase inhibitors, arthralgias, and exercise in breast cancer survivors.. Journal of Clinical Oncology, 2012, 30, TPS669-TPS669.	1.6	3
358	Patterns of decision making about cancer clinical trial participation among the online cancer treatment community: A collaboration between SWOG and NexCura.. Journal of Clinical Oncology, 2012, 30, CRA6009-CRA6009.	1.6	1
359	Patterns of decision making about cancer clinical trial participation among the online cancer treatment community: A collaboration between SWOG and NexCura.. Journal of Clinical Oncology, 2012, 30, CRA6009-CRA6009.	1.6	0
360	Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Research and Treatment, 2011, 126, 529-537.	2.5	687



#	ARTICLE	IF	CITATIONS
361	Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 215-220.	2.5	170
362	Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 767-774.	2.5	211
363	Association Between Prescription Co-Payment Amount and Compliance With Adjuvant Hormonal Therapy in Women With Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2534-2542.	1.6	297
364	Digital optical tomography system for dynamic breast imaging. <i>Journal of Biomedical Optics</i> , 2011, 16, 076014.	2.6	80
365	Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. <i>Cancer</i> , 2010, 116, 2099-2105.	4.1	82
366	Prevention of Bone Loss by Zoledronic Acid in Premenopausal Women Undergoing Adjuvant Chemotherapy Persist up to One Year following Discontinuing Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 559-566.	3.6	47
367	Early Discontinuation and Nonadherence to Adjuvant Hormonal Therapy in a Cohort of 8,769 Early-Stage Breast Cancer Patients. <i>Journal of Clinical Oncology</i> , 2010, 28, 4120-4128.	1.6	663
368	Randomized, Blinded, Sham-Controlled Trial of Acupuncture for the Management of Aromatase Inhibitor-Associated Joint Symptoms in Women With Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1154-1160.	1.6	255
369	Reply to S.A. Narod. <i>Journal of Clinical Oncology</i> , 2010, 28, e700-e700.	1.6	0
370	Patterns of Use and Risks Associated With Erythropoiesis-Stimulating Agents Among Medicare Patients With Cancer. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1633-1641.	6.3	70
371	Reply to R.T. Chlebowski. <i>Journal of Clinical Oncology</i> , 2009, 27, e74-e74.	1.6	0
372	Influence of private practice setting and physician characteristics on the use of breast cancer adjuvant chemotherapy for elderly women. <i>Cancer</i> , 2009, 115, 3848-3857.	4.1	29
373	“Minority report”: how best to analyze clinical trial data to address disparities. <i>Breast Cancer Research and Treatment</i> , 2009, 118, 519-521.	2.5	2
374	Ethnicity and persistent symptom burden in breast cancer survivors. <i>Journal of Cancer Survivorship</i> , 2009, 3, 241-250.	2.9	82
375	Management of complications from estrogen deprivation in breast cancer patients. <i>Current Oncology Reports</i> , 2009, 11, 29-36.	4.0	1
376	Impact of primary prophylaxis on febrile neutropenia within community practices in the US. <i>Journal of Medical Economics</i> , 2009, 12, 203-210.	2.1	20
377	Surgeon Characteristics and Use of Breast Conservation Surgery in Women With Early Stage Breast Cancer. <i>Annals of Surgery</i> , 2009, 249, 828-833.	4.2	71
378	Patients' Perceptions of Physician-Patient Discussions and Adverse Events with Cancer Therapy. <i>Archives of Drug Information</i> , 2008, 1, 70-78.	1.6	11



#	ARTICLE	IF	CITATIONS
379	Doxorubicin, Cardiac Risk Factors, and Cardiac Toxicity in Elderly Patients With Diffuse B-Cell Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 3159-3165.	1.6	336
380	Zoledronic Acid Prevents Bone Loss in Premenopausal Women Undergoing Adjuvant Chemotherapy for Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 4739-4745.	1.6	135
381	Surgeon Characteristics and Receipt of Adjuvant Radiotherapy in Women With Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2008, 100, 199-206.	6.3	86
382	Racial Disparities in Treatment and Survival of Male Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 1089-1098.	1.6	66
383	Prevalence of Joint Symptoms in Postmenopausal Women Taking Aromatase Inhibitors for Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 3877-3883.	1.6	415
384	Acute Myeloid Leukemia or Myelodysplastic Syndrome Following Use of Granulocyte Colony-Stimulating Factors During Breast Cancer Adjuvant Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2007, 99, 196-205.	6.3	260
385	Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients. <i>Journal of Cancer Survivorship</i> , 2007, 1, 283-291.	2.9	74
386	Delay in initiating adjuvant radiotherapy following breast conservation surgery and its impact on survival. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 1353-1360.	0.8	154
387	Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women. <i>Breast Cancer Research and Treatment</i> , 2006, 99, 313-321.	2.5	149
388	Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. <i>Cancer</i> , 2006, 107, 2581-2588.	4.1	164
389	Chemotherapy and Cardiotoxicity in Older Breast Cancer Patients: A Population-Based Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 8597-8605.	1.6	303
390	Racial Disparities in Treatment and Survival Among Women With Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 6639-6646.	1.6	276
391	Treatment of hot flushes in breast and prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1095-1106.	1.8	32
392	Patterns and outcomes of chemotherapy for elderly patients with stage II ovarian cancer: a population-based study. <i>Gynecologic Oncology</i> , 2004, 92, 293-299.	1.4	20
393	Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2004, 94, 540-549.	1.4	64
394	Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer. <i>Current Oncology Reports</i> , 2004, 6, 277-284.	4.0	8
395	Ethnic Neutropenia and Treatment Delay in African American Women Undergoing Chemotherapy for Early-Stage Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1545-1548.	6.3	130
396	Outcomes of Tamoxifen Chemoprevention for Breast Cancer in Very High-Risk Women: A Cost-Effectiveness Analysis. <i>Journal of Clinical Oncology</i> , 2002, 20, 9-16.	1.6	55

#	ARTICLE	IF	CITATIONS
397	Association between immigrant status and advanced cancer patients' location and quality of death. Cancer, 0, , .	4.1	0
398	Efficacy of a password-protected, pill-dispensing device with mail return capacity to enhance disposal of unused opioids after cancer surgery. Cancer, 0, , .	4.1	0